Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma

Stephen E Spurgeon, Kamal Sharma, David F Claxton, Christopher Ehmann, Jeffrey Pu, Sara Shimko, August Stewart, Nan Subbiah, Gundula Palmbach, Francis LeBlanc, Emile Latour, YiYi Chen, Motomi Mori, Zainul Hasanali, Elliot M Epner, Stephen E Spurgeon, Kamal Sharma, David F Claxton, Christopher Ehmann, Jeffrey Pu, Sara Shimko, August Stewart, Nan Subbiah, Gundula Palmbach, Francis LeBlanc, Emile Latour, YiYi Chen, Motomi Mori, Zainul Hasanali, Elliot M Epner

Abstract

Altered DNA methylation and histone acetylation in lymphoma provided the rationale for using vorinostat (SAHA), cladribine and rituximab (SCR) in non-Hodgkin lymphomas (NHL) in this phase 1-2 study (NCT00764517). Treatment included cladribine 5 mg/m2 intravenously (IV) (days 1-5), rituximab 375 mg/m2 IV (weekly 4× for cycle 1 and 1×/month) and vorinostat orally once daily (days 1-14) every 28 days for up to six cycles. Phase 1 included relapsed patients (n = 10) in a standard 3 + 3 dose escalation design (vorinostat: 200, 300 and 400 mg). No dose-limiting toxicities were seen. The phase 2 dose for vorinostat was 400 mg po (days 1-14). The majority of phase 2 patients had mantle cell lymphoma (MCL) (n = 57; 39 previously untreated, 10 relapsed). The primary objective was objective response rate [complete response (CR) + partial response] which was 39% (7/18) in relapsed patients and 97% (38/39) with 80% (31/39) attaining a CR in previously untreated MCL. At a median follow-up of 42 months, median progression-free survival (PFS) and overall survival (OS) for relapsed NHL were 19·5 [95% confidence interval (CI): 2·0-33·0] and 25·0 (95% CI: 12·0-45·0) months respectively. Median PFS for previously untreated MCL was 84·0 months; OS could not be estimated. Toxicities were primarily haematological.

Keywords: epigenetic; mantle cell lymphoma; non-Hodgkin lymphoma; overall response.

© 2019 British Society for Haematology and John Wiley & Sons Ltd.

References

    1. Bobrowicz, M., Dwojak, M., Pyrzynska, B., Stachura, J., Muchowicz, A., Berthel, E., Dalla-Venezia, N., Kozikowski, M., Siernicka, M., Miazek, N., Zapala, P., Domagala, A., Bojarczuk, K., Malenda, A., Barakiewicz, J., Graczyk-Jarzynka, A., Zagozdzon, A., Gabrysiak, M., Diaz, J.J., Karp, M., Lech-Maranda, E., Firczuk, M., Giannopoulos, K., Efremov, D.G., Laurenti, L., Baatout, D., Frenzel, L., Malinowska, A., Slabicki, M., Zenz, T., Zerrougi, A., Golab, J. & Winiarsk, M. (2017) HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood, 130, 1628-1638.
    1. Bouzar, A.B., Boxus, M., Defoiche, J., Berchem, G., Macallan, D., Pettengell, R., Willis, F., Burny, A., Lagneaux, L., Bron, D., Chatelain, B., Chatelain, C. & Willems, L. (2009) Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. British Journal of Haematology, 144, 41-52.
    1. Chandran, R., Gardiner, S.K., Simon, M. & Spurgeon, S.E. (2012) Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007. Leukemia & Lymphoma, 53, 1488-1493.
    1. Chang, J.E., Carmichael, L.L., Kim, K., Peterson, C., Yang, D.T., Traynor, A.M., Werndli, J.E., Huie, M.S., McFarland, T.A., Volk, M., Blank, J., Callander, N.S., Longo, W.L. & Kahl, B.S. (2018) VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network Study. Clinical Lymphoma Myeloma and Leukemia, 18, e61-e67.
    1. Chen, R.W., Li, H. & Bernstein, S.H. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. British Journal of Haematology, 176, 759-769.
    1. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
    1. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
    1. Cotto, M., Cabanillas, F., Tirado, M., Garcia, M.V. & Pacheco, E. (2010) Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clinical and Translational Oncology, 12, 401-409.
    1. Damm, J.K., Gordon, S., Ehinger, M., Jerkeman, M., Gullberg, U., Hultquist, A. & Drott, K. (2015) Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo. Experimental Hematology & Oncology, 4, 4.
    1. Enjuanes, A., Albero, R., Clot, G., Navarro, A., Bea, S., Pinyol, M., Martin-Subero, J.I., Klapper, W., Staudt, L.M., Jaffe, E.S., Rimsza, L., Braziel, R.M., Delabie, J., Cook, J.R., Tubbs, R.R., Gascoyne, R., Connors, J.M., Weisenburger, D.D., Greiner, T.C., Chan, W.C., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Campo, E. & Jares, P. (2013) Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. International Journal of Cancer, 133, 2852-2863.
    1. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
    1. Hasanali, Z.S., Saroya, B.S., Stuart, A., Shimko, S., Evans, J., Vinod Shah, M., Sharma, K., Leshchenko, V.V., Parekh, S., Loughran, T.P. Jr & Epner, E.M. (2015) Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. Science Translational Medicine, 7, 293ra102.
    1. Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., Wormann, B., Trumper, L., Pfreundschuh, M., EinseleH, Hiddermann W., Unterhalt, M. & Dreyling, M. (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. Journal of Clinical Oncology, 27, 511-518.
    1. Hoster, E. & Pott, C. (2016) Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment. Hematology American Society of Hematologic Education Program, 2016, 437-445.
    1. Hoster, E., Kluin-Nelemans, H., Hermine, O., Walewski, J., Trneny, M., Geisler, C.H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J.K., Karlin, L., Forstpointer, R., Tilly, H., Szymczyk, M., Ribrak, V., Andre, M., Klapper, W., Hiddemann, W., Unterhalt, M. & Dreyling, M. (2017) Rituximab maintenance after first-line immunochemotherapy in mantle cell lymphoma: long-term follow-up of the Randomized European MCL Elderly trial. Blood, 130, 153.
    1. Inwards, D.J., Fishkin, P.A., Hillman, D.W., Brown, D.W., Ansell, S.M., Kurtin, P.J., Fonseca, R., Morton, R.F., Veeder, M.H. & Witzig, T.E. (2008) Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer, 113, 108-116.
    1. Inwards, D.J., Fishkin, P.A., LaPlant, B.R., Drake, M.T., Kurtin, P.J., Nikcevich, D.A., Wender, D.B., Lair, B.S. & Witzig, T.E. (2018) Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Annaul of Oncoolgy, 30, 346.
    1. Kanduri, M., Cahill, N., Goransson, H., Enstrom, C., Ryan, F., Isaksson, A. & Rosenquist, R. (2010) Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood, 115, 296-305.
    1. Kluin-Nelemans, H.C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C.H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J.K., Coiffier, B., Forstpointner, R., Tilly, H., Kanz, L., Feugeir, P., Szymczyk, M., Hallek, M., Kremers, S., Lepeu, G., Sanhes, L., Zijlstra, J.M., Bouabdallah, R., Lugtenburg, P.J., Macro, M., Pfreundschuh, M., Prochazka, V., DiRaimondo, F., Ribrag, V., Uppenkamp, M., Anre, M., Klapper, W., Hiddemann, W., Unterhalt, M. & Dreyling, M.H. (2012) Treatment of older patients with mantle-cell lymphoma. New England Journal of Medicine, 367, 520-531.
    1. Kulis, M., Heath, S., Bibikova, M., Queiros, A.C., Navarro, A., Clot, G., Martinez-Trillos, A., Castellano, G., Brun-Heath, I., Pinyol, M., Barberan-Soler, S., Papasaikas, P., Jares, P., Bea, S., Rico, D., Ecker, S., Rubio, M., Royo, R., Ho, V., Klotzle, B., Hernandez, L., Conde, L., Lopez-Guerra, M., Colomer, D., Villamor, N., Aymerich, M., Rozman, B., Bayes, M., Gut, M., Gelpi, J.L., Orozco, M., Fan, J.B., Quesda, V., Puente, X.S., Pisano, D.G., Valencia, A., Lopez-Guillermo, A., Gut, I., Lopez-Otin, C., Campo, E. & Matin-Subero, J.I. (2012) Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nature Genetics, 44, 1236-1242.
    1. LaCasce, A.S., Vandergrift, J.L., Rodriguez, M.A., Abel, G.A., Crosby, A.L., Czuczman, M.S., Nademanee, A.P., Blayney, D.W., Gordon, L.I., Millenson, M., Vanderplas, A., Lepisto, E.M., Zelenetz, A.D., Miland, J. & Friedberg, J.W. (2012) Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood, 119, 2093-2099.
    1. Le Gouill, S., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Dartigeas, C., Damaj, G., Gastinne, T., Ribrag, V., Feugier, P., Casasnovas, O., Zerazhi, H., Haioun, C., Maisonneuve, H., Houot, R., Jardin, F., Van Den Bene, M.D., Salles, G., Tilly, H., Lamy, T., Gressin, R. & Heraine, O. (2017) Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. New England Journal of Medicine, 377, 1250-1260.
    1. Leshchenko, V.V., Kuo, P.Y., Shaknovich, R., Yang, D.T., Gellen, T., Petrich, A., Yu, Y., Remache, Y., Weniger, M.A., Rafiq, S., Suh, K.S., Goy, A., Wilson, W., Verma, A., BraunschweigI Muthusamy, N., Kahl, B.S., Byrd, J.C., Wiestner, A., Metrick, A. & Parekh, S. (2010) Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood, 116, 1025-1034.
    1. Liu, H., Wang, J. & Epner, E.M. (2004) Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. Blood, 104, 2505-2513.
    1. Obr, A., Prochazka, V., Jirkuvova, A., Urbankova, H., Kriegova, E., Schneiderova, P., Vatolikova, M. & Papajik, T. (2018) TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma. Clinical Lymphoma Myeloma Leukemia, 18, 762-768.
    1. Pera, B., Tang, T., Marullo, R., Yang, S.N., Ahn, H., Patel, J., Elstrom, R., Ruan, J., Furman, R., Leonard, J., Cerchietti, L. & Martin, P. (2016) Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clinical Epigenetics, 8, 79.
    1. Puvvada, S.D., Guillen-Rodriguez, J., Kumar, A., Inclan, L., Heard, K., Rivera, X.I., Anwer, F., Schatz, J.H., Mahadevan, D. & Persky, D.O. (2018) Phase 2 open-label study of bortezomib, cladribine, and rituximab in advanced, newly diagnosed, and relapsed/refractory mantle-cell and indolent lymphomas. Clinical Lymphoma Myeloma Leukemia, 18, 58-64.
    1. Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., Alexeeva, J., Pereira, J., Drach, J., Mayer, J., Hong, X., Okamoto, R., Pei, L., Roonery, B., Van de Velde, H. & Cavalli, F. (2015) Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. New England Journal ofMedicine, 372, 944-953.
    1. Ruan, J., Martin, P., Christos, P., Cerchietti, L., Tam, W., Shah, B., Schuster, S.J., Rodriguez, A., Hyman, D., Calvo-Vidal, M.N., Smith, S.M., Svoboda, J., Fuman, R.R., Coleman, M. & Leonard, J.P. (2018) Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood, 132, 2016-2025.
    1. Sakajiri, S., Kumagai, T., Kawamata, N., Saitoh, T., Said, J.W. & Koeffler, H.P. (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Experimental Hematology, 33, 53-61.
    1. Schmidt, C. & Dreyling, M. (2008) Therapy of mantle cell lymphoma: current standards and future strategies. Hematolology Oncololgy Clinical North America, 22, 953-963, ix.
    1. Shimizu, R., Kikuchi, J., Wada, T., Ozawa, K., Kano, Y. & Furukawa, Y. (2010) HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia, 24, 1760-1768.
    1. Simonsen, A.T., Sorensen, C.D., Ebbesen, L.H., Bodker, J.S., Bentzen, H.H. & Nyvold, C.G. (2014) SOX11 as a minimal residual disease marker for Mantle cell lymphoma. Leukemia Research, 38, 918-924.
    1. Spurgeon, S., Yu, M., Phillips, J.D. & Epner, E.M. (2009) Cladribine: not just another purine analogue? Expert Opinion on Investigational Drugs, 18, 1169-1181.
    1. Spurgeon, S.E., Pindyck, T., Okada, C., Chen, Y., Chen, Z., Mater, E., Abbi, K. & Epner, E.M. (2011) Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leukemia and Lymphoma, 52, 1488-1494.
    1. Tam, C.S., Anderson, M.A., Pott, C., Agarwal, R., Handunnetti, S., Hicks, R.J., Burbury, K., Turner, G., Di Iulio, J., Bressel, M., Westerman, D., Lade, S., Dreyling, M., Dawson, M.A., Seymour, J.F. & Roberts, A.W. (2018) Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. New England Journal of Medicine, 378, 1211-1223.
    1. Visco, C., Chiappella, A., Nassi, L., Patti, C., Ferrero, S., Barbero, D., Evangelista, A., Spina, M., Molinari, A., Rigacci, L., Tani, M., Rocco, A.D., Pinotti, G., Fabbri, A., Zambello, R., Finotto, S., Gotti, M., Carella, A.M. & Salvi, F. (2017) Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematoogy, 4, e15-e23.
    1. Watanabe, T., Kato, H., Kobayashi, Y., Yamasaki, S., Morita-Hoshi, Y., Yokoyama, H., Morishima, Y., Ricker, J.L., Otsuki, T., Matsuno, Y. & Tobinai, K. (2010) Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Science, 101, 196-200.
    1. Wyczechowska, D. & Fabianowska-Majewska, K. (2003) The effects of cladribine and fludarabine on DNA methylation in K562 cells. Biochemical Pharmacology, 65, 219-225.
    1. Xue, K., Gu, J.J., Zhang, Q., Mavis, C., Hernandez-Ilizaliturri, F.J., Czuczman, M.S. & Guo, Y. (2016) Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. Journal of Cancer Research and Clinical Oncology, 142, 379-387.
    1. Zelenetz, A.D., Gordon, L.I., Wierda, W.G., Abramson, J.S., Advani, R.H., Andreadis, C.B., Bartlett, N., Byrd, J.C., Czuczman, M.S., Fayad, L.E., Fisher, R.I., Glenn, M.J., Harris, N.L., Hoppe, R.T., Horwitz, S.M., Kelsey, C.R., Kim, Y.H., Krivacic, S., LaCasce, A.S., Nademanee, A., Porcu, P., Press, O., Rabinovitch, R., Reddy, N., ReidE, Saad A.A., Sokol, L., Swinnen, L.J., Tsien, C., Vose, J.M., Yahalom, J., Zafar, N., Swyer, M. & Sundar, H. (2014) Non-Hodgkin's lymphomas, version 4.2014. Journal of National Comprehensive Cancer Network, 12, 1282-1303.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅